Michel Sadelain
37Patents
7h-index
38Co-inventors
69Inventor score
Filing activity: Sep 18, 1998 → Jun 13, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7446190B2 | Nucleic acids encoding chimeric T cell receptors | Chemistry; Metallurgy | 369 | Expired |
| US8389282B2 | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes | Emerging Cross-Sectional Technologies | 208 | Active |
| US6451995B1 | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods | Chemistry; Metallurgy | 89 | Expired |
| US9220728B2 | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes | Emerging Cross-Sectional Technologies | 36 | Active |
| US10370452B2 | Effective generation of tumor-targeted T cells derived from pluripotent stem cells | Chemistry; Metallurgy | 14 | Active |
| US10117897B2 | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes | Emerging Cross-Sectional Technologies | 10 | Active |
| US10654928B2 | Compositions and methods for immunotherapy | Chemistry; Metallurgy | 9 | Active |
| US11267901B2 | Compositions and methods for immunotherapy | Chemistry; Metallurgy | 7 | Active |
| US11242375B2 | Immune cell compositions and methods of use | Chemistry; Metallurgy | 5 | Active |
| US6642043B1 | Double mutants of dihydrofolate reductase and methods of using same | Chemistry; Metallurgy | 5 | Expired |
| US10350243B2 | Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors | Chemistry; Metallurgy | 3 | Active |
| US7541179B2 | Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies | Chemistry; Metallurgy | 3 | Expired |
| US11229669B2 | Cells comprising non-HLA restricted T cell receptors | Chemistry; Metallurgy | 3 | Active |
| US11932690B2 | Enhanced chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US11377637B2 | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods | Emerging Cross-Sectional Technologies | 2 | Active |
| US8058061B2 | Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies | Chemistry; Metallurgy | 2 | Active |
| US10633441B2 | Mesothelin-targeted chimeric antigen receptors and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US11702472B2 | Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors | Chemistry; Metallurgy | 0 | Active |
| US12263220B2 | Compositions and methods for immunotherapy | Chemistry; Metallurgy | 0 | Active |
| US12018077B2 | Methods of treatments using antigen-binding proteins targeting CD56 | Chemistry; Metallurgy | 0 | Active |
| US10538588B2 | Mesothelin-targeted chimeric antigen receptors and methods of making them | Chemistry; Metallurgy | 0 | Active |
| US11717579B2 | Globin gene therapy for treating hemoglobinopathies | Chemistry; Metallurgy | 0 | Active |
| US12331129B2 | Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12036244B2 | Cells comprising non-HLA restricted T cell receptors | Chemistry; Metallurgy | 0 | Active |
| US10059923B2 | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.